FORMULATION AND IN VITRO CHARACTERIZATION OF THE SOLID LIPID NANOPARTICLES OF NAFTOPIDIL FOR ENHANCING ORAL BIOAVAILABILITY

Objective: Naftopidil (NAF) is a selective alpha1-adrenergic receptor antagonist with nearly 20% bioavailability due to poor aqueous solubility, permeability, and extensive first-pass metabolism. To improve the of NAF, solid lipid nanoparticles (SLN) NAF were prepared. Methods: SLNs prepared using solvent emulsification/evaporation method excipients Compritol 888 ATO Poloxamer 188. Formulation F10 shows better entrapment efficiency (EE) as compare other formulations so, it has selected optimize particle size, zeta potential, surface morphology, Fourier transform infrared spectroscopy (FTIR), in vitro drug release stability studies assessed. Results: The results showed that was successfully incorporated SLN. Having EE all ranged from 56% 88%, loading 17% 20%, content 77% 98%, size potential 270.2 nm 21.7 mV, respectively, FTIR revealed no interaction between formulation. NAF-SLNs increased significantly, reaching maximum 4.547–82.418% pH 6.8 buffer, data fitted into Korsmeyer-Peppas model yielding highest correlation coefficient (R2=0.916). study formulation might be improved. Conclusion: It can concluded SLN could effective nanoplatforms for increasing oral bioavailability.